743 related articles for article (PubMed ID: 3081257)
1. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Camiolo SM; Greco WR
Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.
Liu JN; Gurewich V
J Clin Invest; 1991 Dec; 88(6):2012-7. PubMed ID: 1836471
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators in human malignant melanoma.
Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C
J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238
[TBL] [Abstract][Full Text] [Related]
4. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
Kawakami K; Takahashi A; Yoshimoto T
No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
[TBL] [Abstract][Full Text] [Related]
5. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
Lijnen HR; Wagner EF; Collen D
Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
[TBL] [Abstract][Full Text] [Related]
7. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
9. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
10. [Intraglomerular coagulation and fibrinolysis in human primary glomerular diseases].
Shibata K; Dohi K; Fujii Y; Ishikawa H
Nihon Jinzo Gakkai Shi; 1991 Aug; 33(8):719-29. PubMed ID: 1770632
[TBL] [Abstract][Full Text] [Related]
11. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
Gurewich V; Pannell R; Broeze RJ; Mao J
J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
[TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator activity in human aqueous humor.
Smalley DM; Fitzgerald JE; Taylor DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Jan; 35(1):48-53. PubMed ID: 8300363
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the plasminogen activator activity units of urinary-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA).
Creighton-Kempsford LJ; Pring JB; Gaffney PJ
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):481-3. PubMed ID: 1420825
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
19. [New thrombolytic agents].
Nguyen G; Samama M
Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
[TBL] [Abstract][Full Text] [Related]
20. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
Orbe J; Chordá C; Montes R; Páramo JA
Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
